Europe Genome Sequencing Market to Grow with a CAGR of 15.06% through 2030
Expanding
applications of genome sequencing in clinical research and advancements in
sequencing technologies, is expected to drive the Europe Genome Sequencing
Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Europe Genome Sequencing Market – By Country, Competition, Forecast & Opportunities, 2030F”, the Europe Genome
Sequencing Market was valued at USD
2.47 Billion in 2024 and is expected to reach USD 5.74 Billion by
2030 with a CAGR of 15.06%.
The Europe Genome Sequencing Market is evolving rapidly, driven by the growing
need for accurate, data-driven approaches to healthcare. The rising incidence
of rare and undiagnosed conditions is encouraging the use of genome sequencing
as a frontline diagnostic tool. Public and private sector organizations are
showing increased interest in incorporating genomic data into population health
initiatives and therapeutic research. The market is also benefiting from the
increasing demand for early disease detection tools, supported by healthcare
providers seeking more precise and cost-effective clinical solutions. Patient
awareness about the benefits of genetic testing is also contributing to the
uptake of sequencing services across various health conditions.
Technological
convergence is shaping new possibilities in genome sequencing workflows.
Automation in sample preparation, innovations in sequencing chemistry, and
real-time data processing are enhancing lab productivity and throughput.
Direct-to-consumer genetic testing companies are gaining traction, with
individuals seeking insights into ancestry, inherited traits, and health
predispositions. Multi-omics integration—combining genomics with proteomics,
metabolomics, and transcriptomics—is emerging as a transformative trend,
enabling a deeper understanding of disease biology. As pharmaceutical firms
pursue biomarker discovery and companion diagnostics development, genome
sequencing is becoming integral to personalized therapy pipelines. Demand for
software platforms that can efficiently handle, analyze, and interpret massive
genomic datasets is also increasing.
Significant
growth opportunities lie in expanding genome sequencing applications beyond
human health. Agricultural genomics, environmental monitoring, and microbial
genome analysis are emerging areas where sequencing technologies are finding
new relevance. Strategic investments in decentralized testing models such as
mobile genome labs and point-of-care solutions can unlock access in rural and
remote areas. Increased participation in international genomics collaborations
and large-scale biobanking initiatives can also provide a boost to research and
clinical innovation. Companies that focus on user-friendly interfaces,
transparent reporting, and scalable sequencing solutions will be
well-positioned to tap into the growing demand across clinical and non-clinical
domains.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Europe Genome Sequencing Market”
The Europe Genome
Sequencing Market is segmented into product, technology, application, end user,
country distribution, and company.
Based on the Application,
Clinical emerged as the fastest growing segment in the Europe Genome Sequencing
Market during the forecast period. This is due to the increasing adoption of
genomic data in clinical decision-making and personalized medicine. Genome
sequencing is becoming integral in clinical settings, particularly in oncology,
rare genetic diseases, prenatal diagnostics, and pharmacogenomics. As more
hospitals and healthcare providers integrate sequencing technologies into
routine practice, the demand for clinical applications is accelerating. The
ability of genome sequencing to identify genetic mutations, predict disease
risks, and tailor personalized treatment plans has made it an essential tool
for improving patient outcomes. In oncology, for example, sequencing helps identify
specific mutations that drive cancer progression, allowing for targeted
therapies that increase treatment efficacy.
Based
on the Country, United Kingdom emerged as the fastest growing country in the Europe
Genome Sequencing Market during
the forecast period. This is due to its strong focus on genomics research,
advancements in healthcare, and the integration of sequencing technologies into
clinical practices. The UK has positioned itself as a leader in genomics,
supported by initiatives such as the 100,000 Genomes Project, which aims to
expand the use of genome sequencing in the diagnosis and treatment of rare
diseases and cancers. This national effort has significantly boosted the
adoption of genomic technologies across healthcare settings, particularly in
public healthcare institutions like the National Health Service (NHS). The UK's
commitment to precision medicine, evidenced by substantial funding for
genomics-based research and infrastructure, has driven rapid growth in the
application of genome sequencing. As healthcare systems in the UK embrace
data-driven, personalized treatment plans, demand for advanced sequencing
technologies, especially next-generation sequencing (NGS), has surged.
Major
companies operating in Europe Genome Sequencing Market are:
- Oxford
Nanopore Technologies
- CeGaT
GmbH
- BioVariance
GmbH
- BaseClear
B.V.
- Macrogen
Europe
- Congenica
- Repositive
Ltd.
- STRATEC
SE
- Scilifelab
GmbH
- Eligo
Bioscience
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Europe Genome Sequencing Market is
expanding due to the growing integration of genome sequencing into drug
development and clinical trials. Pharmaceutical companies are increasingly
utilizing genomic data to identify biomarkers, optimize drug efficacy, and
personalize therapies during the clinical trial process. By leveraging genome
sequencing, they can better understand patient responses, improve drug safety,
and accelerate the development of targeted therapies, particularly in oncology
and rare diseases. This trend is also facilitating the development of companion
diagnostics that are essential for the success of new drug therapies. The
application of genomic data in drug discovery and clinical research is driving
market growth and fostering innovations in precision medicine.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Europe Genome Sequencing
Market By Product (Consumables, Software, Instrument), By Technology
(Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, Sanger
Sequencing, Others), By Application (Clinical, Non-Clinical), By End User
(Academic and Government Research Institutes, Hospitals & Clinics,
Pharmaceutical and Biotechnology Companies, Others), By Country, Competition,
Forecast and Opportunities, 2020-2030F”, has evaluated
the future growth potential of Europe Genome Sequencing Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Europe Genome Sequencing Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com